Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy

• Published in: Minerva medica Vol. 104; no. 1; p. 93
• Main Authors: Cetin, E, Civelek, S, Andican, G, Candan Polizzi, F, Yumuk, V, Burçak, G
• Format: Journal Article
• Language: English
• Published: Italy 01-02-2013
• Subjects: Aged; Aged, 80 and over; Blood Glucose - analysis; C-Peptide - blood; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetic Nephropathies - blood; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - pathology; Female; Glycated Hemoglobin A - analysis; Glycation End Products, Advanced - blood; Humans; Male; Middle Aged; Pyridoxal Phosphate - blood; Pyridoxine - therapeutic use; Thiamine - therapeutic use; Thiamine Pyrophosphate - blood; Triglycerides - blood; Vitamin B Complex - therapeutic use
• ISSN: 0026-4806

The aim of the study was to evaluate circulatory AGE-peptide levels in diabetic nephropathy and to observe the effects of thiamine (vitamin B1) and pyridoxine (vitamin B6) therapy.
Type 2 diabetic patients (N.=57) were divided into two groups as "with nephropathy" (N.=27) and "without nephropathy" (N.=30). Diabetic nephropathy patients were treated with either B6 (N.=12) (250 mg/day) or B1+B6 (N.=15) (250 mg/day, each) for five months. At the beginning and the end of the experimentation period, glucose, HbA1c, triglyceride, cholesterol, insulin, C-peptide, thiamine pyrophosphate, pyridoxal phosphate and AGE- peptides were measured.
AGE-peptides were higher in the diabetic group with nephropathy than without nephropathy (P=0.005). Within five months AGE-peptides increased in the diabetic group without nephropathy (P=0.042) but not in the group with nephropathy treated either with B1+B6 or B6. In B6 treated group a substantial decrease was observed in HbA1c (P=0.033). B1+B6 or B6 treatment both caused an increase in C-peptide (P=0.006, P=0.004).
Among the parameters measured, plasma AGE-peptides was the only parameter found to be higher in type 2 diabetes mellitus patients "with nephropathy" than "without nephropathy". However, patients with nephropathy treated with B1+B6 or B6 did not display any further increase in AGE-peptides within five months. Both of the treatments caused an increase in C-peptide.